Apogee Therapeutics, Inc Common Stock
Yahoo Finance • 3 months ago
Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares
Michael Henderson, the CEO of Apogee Therapeutics Inc (NASDAQ:APGE), sold 40,000 shares of the company on August 7, 2024. The transaction was disclosed in a recent SEC Filing. Following this sale, the insider now owns 1,434,487 shares of t... Full story
Yahoo Finance • last year
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in... Full story
Yahoo Finance • last year
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chron... Full story
Yahoo Finance • last year
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), ast... Full story
Yahoo Finance • last year
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic... Full story
Yahoo Finance • last year
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized... Full story
Yahoo Finance • last year
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic... Full story
